$RXST
RxSight, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023062099 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $28.58M $22.20M
YoY Change 77.65% 75.97%
Cost Of Revenue $10.93M $8.468M
YoY Change 26.08% 16.66%
Gross Profit $17.65M $13.73M
YoY Change 137.86% 156.37%
Gross Profit Margin 61.77% 61.85%
Selling, General & Admin $21.18M $19.14M
YoY Change 34.03% 28.25%
% of Gross Profit 119.98% 139.41%
Research & Development $7.292M $7.101M
YoY Change 10.5% 11.16%
% of Gross Profit 41.31% 51.72%
Depreciation & Amortization $1.084M $1.130M
YoY Change 12.8% 15.31%
% of Gross Profit 6.14% 8.23%
Operating Expenses $28.51M $26.24M
YoY Change 27.19% 23.13%
Operating Profit -$10.85M -$12.51M
YoY Change -27.61% -21.59%
Interest Expense $1.657M $230.0K
YoY Change -369.43% -82.29%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$9.195M -$12.40M
YoY Change -41.08% -26.25%
Income Tax -$18.00K $12.00K
% Of Pretax Income
Net Earnings -$9.177M -$12.42M
YoY Change -41.21% -26.18%
Net Earnings / Revenue -32.11% -55.93%
Basic Earnings Per Share -$0.35
Diluted Earnings Per Share -$0.26 -$0.35
COMMON SHARES
Basic Shares Outstanding 35.86M 35.64M
Diluted Shares Outstanding 35.66M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $127.2M $131.9M
YoY Change 20.21% 16.9%
Cash & Equivalents $9.692M $9.859M
Short-Term Investments $117.5M $122.0M
Other Short-Term Assets $3.523M $1.900M
YoY Change 18.94% -3.6%
Inventory $17.42M $18.92M
Prepaid Expenses
Receivables $20.28M $15.24M
Other Receivables $0.00 $0.00
Total Short-Term Assets $168.4M $167.9M
YoY Change 25.16% 20.68%
LONG-TERM ASSETS
Property, Plant & Equipment $10.84M $10.26M
YoY Change 6.93% -3.37%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $147.0K $137.0K
YoY Change -80.83% -82.48%
Total Long-Term Assets $14.14M $13.90M
YoY Change -9.39% -15.96%
TOTAL ASSETS
Total Short-Term Assets $168.4M $167.9M
Total Long-Term Assets $14.14M $13.90M
Total Assets $182.6M $181.9M
YoY Change 21.57% 16.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.863M $4.105M
YoY Change 48.86% -1.61%
Accrued Expenses $15.24M $14.80M
YoY Change 20.26% 22.96%
Deferred Revenue $2.045M
YoY Change 51.71%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $37.00K $0.00
YoY Change -75.66% -100.0%
Total Short-Term Liabilities $20.90M $18.94M
YoY Change 21.27% 15.73%
LONG-TERM LIABILITIES
Long-Term Debt $118.0K $0.00
YoY Change -99.71% -100.0%
Other Long-Term Liabilities $1.167M $1.400M
YoY Change -58.51% -57.32%
Total Long-Term Liabilities $1.285M $1.400M
YoY Change -97.01% -96.77%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.90M $18.94M
Total Long-Term Liabilities $1.285M $1.400M
Total Liabilities $22.19M $20.37M
YoY Change -63.18% -65.9%
SHAREHOLDERS EQUITY
Retained Earnings -$594.6M -$585.5M
YoY Change 8.9% 10.38%
Common Stock $36.00K $36.00K
YoY Change 28.57% 28.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $160.4M $161.5M
YoY Change
Total Liabilities & Shareholders Equity $182.6M $181.9M
YoY Change 21.57% 16.79%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$9.177M -$12.42M
YoY Change -41.21% -26.18%
Depreciation, Depletion And Amortization $1.084M $1.130M
YoY Change 12.8% 15.31%
Cash From Operating Activities -$8.301M -$7.980M
YoY Change -40.08% -47.46%
INVESTING ACTIVITIES
Capital Expenditures $1.591M $650.0K
YoY Change 339.5% -212.07%
Acquisitions
YoY Change
Other Investing Activities $6.157M $17.93M
YoY Change -42.82% 1472.81%
Cash From Investing Activities $4.566M $17.27M
YoY Change -56.12% 2983.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.562M -8.240M
YoY Change -43.52% 1710.99%
NET CHANGE
Cash From Operating Activities -8.301M -7.980M
Cash From Investing Activities 4.566M 17.27M
Cash From Financing Activities 3.562M -8.240M
Net Change In Cash -173.0K 1.050M
YoY Change -106.05% -106.96%
FREE CASH FLOW
Cash From Operating Activities -$8.301M -$7.980M
Capital Expenditures $1.591M $650.0K
Free Cash Flow -$9.892M -$8.630M
YoY Change -30.42% -40.92%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001111485
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet
CY2022Q4 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet
CY2023Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://rxsight.com/20230930#LeaseLiabilitiesCurrent
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://rxsight.com/20230930#LeaseLiabilitiesCurrent
CY2023Q3 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://rxsight.com/20230930#LeaseLiabilitiesCurrent
CY2022Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://rxsight.com/20230930#LeaseLiabilitiesCurrent
CY2023Q3 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://rxsight.com/20230930#LeaseLiabilitiesNoncurrent
CY2022Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://rxsight.com/20230930#LeaseLiabilitiesNoncurrent
CY2023Q3 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://rxsight.com/20230930#LeaseLiabilitiesNoncurrent
CY2022Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://rxsight.com/20230930#LeaseLiabilitiesNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40690
dei Entity Registrant Name
EntityRegistrantName
RxSIGHT, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3268801
dei Entity Address Address Line1
EntityAddressAddressLine1
100 Columbia
dei Entity Address City Or Town
EntityAddressCityOrTown
Aliso Viejo
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92656
dei City Area Code
CityAreaCode
949
dei Local Phone Number
LocalPhoneNumber
521-7830
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
RXST
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35861604
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9859000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11834000
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
122023000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
93968000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15244000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10956000
CY2023Q3 us-gaap Inventory Net
InventoryNet
18924000
CY2022Q4 us-gaap Inventory Net
InventoryNet
14835000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1897000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2962000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
167947000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
134555000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10262000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10138000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2793000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3943000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
711000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
761000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
137000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
767000
CY2023Q3 us-gaap Assets
Assets
181850000
CY2022Q4 us-gaap Assets
Assets
150164000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4105000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2595000
CY2023Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
12861000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
12672000
CY2023Q3 rxst Lease Liabilities Current
LeaseLiabilitiesCurrent
1976000
CY2022Q4 rxst Lease Liabilities Current
LeaseLiabilitiesCurrent
1970000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
18942000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17237000
CY2023Q3 rxst Lease Liabilities Noncurrent
LeaseLiabilitiesNoncurrent
1354000
CY2022Q4 rxst Lease Liabilities Noncurrent
LeaseLiabilitiesNoncurrent
2856000
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
0
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
40169000
CY2023Q3 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
75000
CY2022Q4 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
0
CY2023Q3 us-gaap Liabilities
Liabilities
20371000
CY2022Q4 us-gaap Liabilities
Liabilities
60262000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35847685
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35847685
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28268389
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28268389
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
36000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
28000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
746966000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
636001000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-60000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-95000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-585463000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-546032000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
161479000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
89902000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
181850000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
150164000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
22199000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12615000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
60497000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
32917000
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8468000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7259000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
24386000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
19011000
CY2023Q3 us-gaap Gross Profit
GrossProfit
13731000
CY2022Q3 us-gaap Gross Profit
GrossProfit
5356000
us-gaap Gross Profit
GrossProfit
36111000
us-gaap Gross Profit
GrossProfit
13906000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
19142000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14926000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
53634000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
42934000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7101000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6388000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21710000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19300000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
26243000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
21314000
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
us-gaap Operating Expenses
OperatingExpenses
75344000
us-gaap Operating Expenses
OperatingExpenses
62234000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12512000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15958000
us-gaap Operating Income Loss
OperatingIncomeLoss
-39233000
us-gaap Operating Income Loss
OperatingIncomeLoss
-48328000
CY2023Q3 us-gaap Interest Expense
InterestExpense
230000
CY2022Q3 us-gaap Interest Expense
InterestExpense
1299000
us-gaap Interest Expense
InterestExpense
3304000
us-gaap Interest Expense
InterestExpense
3495000
CY2023Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
1746000
CY2022Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
439000
us-gaap Interest And Other Income
InterestAndOtherIncome
4913000
us-gaap Interest And Other Income
InterestAndOtherIncome
681000
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1407000
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1769000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12403000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16818000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39393000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-51142000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
38000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-12415000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-16818000
us-gaap Net Income Loss
NetIncomeLoss
-39431000
us-gaap Net Income Loss
NetIncomeLoss
-51146000
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
19000
CY2022Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
55000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
38000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-95000
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-6000
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-10000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-3000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-23000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
13000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
45000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
35000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-118000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12402000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16773000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39396000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-51264000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.86
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.86
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35662397
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35662397
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27665842
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27665842
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33947331
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33947331
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27551333
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27551333
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
89902000
CY2023Q1 rxst Shares Issued For The Exercise Of Stock Options And Vesting Of Restricted Stock Units Amount
SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount
761000
CY2023Q1 rxst Shares Redeemed For Employee Tax With Holdings Amount
SharesRedeemedForEmployeeTaxWithHoldingsAmount
-337000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3295000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
53600000
CY2023Q1 rxst Issuance Of Common Stock In At The Market Offerings Net Of Issuance Costs Amount
IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount
10914000
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
84000
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
2000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-13212000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
145009000
CY2023Q2 rxst Shares Issued For The Exercise Of Stock Options And Vesting Of Restricted Stock Units Amount
SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount
2599000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3955000
CY2023Q2 rxst Shares Issued For The Employee Stock Purchase Plan Amount
SharesIssuedForTheEmployeeStockPurchasePlanAmount
536000
CY2023Q2 rxst Issuance Of Common Stock In At The Market Offerings Net Of Issuance Costs Amount
IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount
18957000
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-65000
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
1000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-13804000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
157188000
CY2023Q3 rxst Shares Issued For The Exercise Of Stock Options And Vesting Of Restricted Stock Units Amount
SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount
1994000
CY2023Q3 rxst Shares Redeemed For Employee Tax With Holdings Amount
SharesRedeemedForEmployeeTaxWithHoldingsAmount
-1084000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4071000
CY2023Q3 rxst Issuance Of Common Stock In At The Market Offerings Net Of Issuance Costs Amount
IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount
11712000
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
19000
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-6000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-12415000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
161479000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
138242000
CY2022Q1 rxst Shares Issued For The Exercise Of Stock Options And Vesting Of Restricted Stock Units Amount
SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount
308000
CY2022Q1 rxst Shares Redeemed For Employee Tax With Holdings Amount
SharesRedeemedForEmployeeTaxWithHoldingsAmount
-362000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2649000
CY2022Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-74000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-4000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-17596000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
123163000
CY2022Q2 rxst Shares Issued For The Exercise Of Stock Options And Vesting Of Restricted Stock Units Amount
SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount
277000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2904000
CY2022Q2 rxst Shares Issued For The Employee Stock Purchase Plan Amount
SharesIssuedForTheEmployeeStockPurchasePlanAmount
459000
CY2022Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-76000
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-9000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-16732000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
109986000
CY2022Q3 rxst Shares Issued For The Exercise Of Stock Options And Vesting Of Restricted Stock Units Amount
SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount
145000
CY2022Q3 rxst Shares Redeemed For Employee Tax With Holdings Amount
SharesRedeemedForEmployeeTaxWithHoldingsAmount
-281000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2882000
CY2022Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
55000
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-10000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-16818000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
95959000
us-gaap Profit Loss
ProfitLoss
-39431000
us-gaap Profit Loss
ProfitLoss
-51146000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3027000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2966000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
132000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
95000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
287000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
408000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1769000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-0
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
4545000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
622000
us-gaap Share Based Compensation
ShareBasedCompensation
11321000
us-gaap Share Based Compensation
ShareBasedCompensation
8435000
us-gaap Inventory Write Down
InventoryWriteDown
13000
us-gaap Inventory Write Down
InventoryWriteDown
454000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4288000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4159000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4101000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
7758000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-997000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1613000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1408000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2331000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
119000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2387000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33292000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44996000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3223000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2031000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
205000000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
210000000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
228472000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
178424000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-26695000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
29545000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
20000000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0
rxst Repayment Of Term Loan
RepaymentOfTermLoan
60000000
rxst Repayment Of Term Loan
RepaymentOfTermLoan
0
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
54050000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
rxst Proceeds From Issuance Of Common Stock In At The Market Offerings
ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings
42433000
rxst Proceeds From Issuance Of Common Stock In At The Market Offerings
ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5890000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1189000
rxst Payments For Employee Taxes Related To Stock Compensation
PaymentsForEmployeeTaxesRelatedToStockCompensation
-1421000
rxst Payments For Employee Taxes Related To Stock Compensation
PaymentsForEmployeeTaxesRelatedToStockCompensation
-643000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
119000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
82000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
647000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
295000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
2224000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
144000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
57962000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-2000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-23000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2026000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15449000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12595000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25172000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10569000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9723000
us-gaap Operating Lease Payments
OperatingLeasePayments
1666000
us-gaap Operating Lease Payments
OperatingLeasePayments
1518000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
12000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
3000
rxst Interest Paid On Financing Leases
InterestPaidOnFinancingLeases
8000
rxst Interest Paid On Financing Leases
InterestPaidOnFinancingLeases
12000
rxst Interest Paid On Term Loan
InterestPaidOnTermLoan
3464000
rxst Interest Paid On Term Loan
InterestPaidOnTermLoan
3025000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
8000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1090000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
311000
rxst Operating Lease Obligations Incurred
OperatingLeaseObligationsIncurred
8000
rxst Operating Lease Obligations Incurred
OperatingLeaseObligationsIncurred
1090000
rxst Finance Lease Obligations Incurred
FinanceLeaseObligationsIncurred
0
rxst Finance Lease Obligations Incurred
FinanceLeaseObligationsIncurred
280000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
211000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
151000
rxst Deferred Offering Costs Included In Accrued Expenses
DeferredOfferingCostsIncludedInAccruedExpenses
159000
rxst Deferred Offering Costs Included In Accrued Expenses
DeferredOfferingCostsIncludedInAccruedExpenses
350000
rxst Reclassification Of Deferred Cost
ReclassificationOfDeferredCost
1300000
rxst Reclassification Of Deferred Cost
ReclassificationOfDeferredCost
0
rxst Number Of Wholly Owned Subsidiaries
NumberOfWhollyOwnedSubsidiaries
1
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
131900000
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
105800000
CY2023Q3 rxst Operating Income Loss1
OperatingIncomeLoss1
12500000
CY2022Q3 rxst Operating Income Loss1
OperatingIncomeLoss1
16000000
rxst Operating Income Loss1
OperatingIncomeLoss1
39200000
rxst Operating Income Loss1
OperatingIncomeLoss1
48300000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make informed estimates, judgments and assumptions that affect the reported amounts in the condensed consolidated financial statements and disclosures in the accompanying notes as of the date of the accompanying condensed consolidated financial statements. On an on-going basis, management evaluates the most critical estimates and assumptions for continued reasonableness. Actual results may differ materially from the estimates used in the preparation of the accompanying condensed consolidated financial statements under different assumptions or conditions.</span></p>
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.628
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
38000000
CY2022 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
75000000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. The Company’s policy is to invest cash in institutional money market funds and marketable securities of the U.S. government to limit the amount of credit exposure. The Company currently maintains a portfolio of cash equivalents and short-term investments in money</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market funds and U.S. treasury bills. A portion of the Company's operating cash is held in accounts in excess of the Federal Deposit Insurance Corporation (“FDIC”) insurance limits; however, the Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. The Company has not experienced material losses on cash equivalents and short-term investments.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s products require approval from the FDA and foreign regulatory agencies before commercial sales can commence. There can be no assurance that the Company’s products will receive any of these required approvals. The denial or delay of such approvals may have a material adverse impact on the Company’s business and may impact business in the future. In addition, after approval by the FDA, there is still an ongoing risk of adverse events that did not appear during the device approval process.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of the Company's products, product liability and the need to obtain additional financing.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to the risks related to global lead times, particularly in Europe and Asia, leading to a supply interruption from the Company's suppliers. In addition, the Company is currently experiencing inflation and longer lead times and limited availability in its supply chain for certain components and has continued exposure to price and supply risk related to anticipated purchases of certain commodities, materials and products used in its business.</span></p>
rxst Accounts Receivable Percentage
AccountsReceivablePercentage
0.10
CY2022 rxst Accounts Receivable Percentage
AccountsReceivablePercentage
0.10
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
22199000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12615000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
60497000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
32917000
CY2023Q3 us-gaap Deferred Revenue
DeferredRevenue
1678000000
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
1187000000
CY2022Q4 rxst Deferred Revenue1
DeferredRevenue1
-1187000
CY2021Q4 rxst Deferred Revenue1
DeferredRevenue1
-540000
us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
2427000
us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
1417000
us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
1936000
us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
916000
CY2023Q3 rxst Deferred Revenue1
DeferredRevenue1
-1678000
CY2022Q3 rxst Deferred Revenue1
DeferredRevenue1
-1041000
CY2023Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
8734000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
6408000
CY2023Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
5771000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
6494000
CY2023Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
4787000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
2567000
CY2023Q3 us-gaap Inventory Gross
InventoryGross
19292000
CY2022Q4 us-gaap Inventory Gross
InventoryGross
15469000
CY2023Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
368000
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
634000
CY2023Q3 us-gaap Inventory Net
InventoryNet
18924000
CY2022Q4 us-gaap Inventory Net
InventoryNet
14835000
CY2023Q3 us-gaap Other Inventory Materials Supplies And Merchandise Under Consignment
OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
5200000
CY2022Q4 us-gaap Other Inventory Materials Supplies And Merchandise Under Consignment
OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
2800000
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
128246000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
102877000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
9600000
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
6100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.653
rxst Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate
0.041
rxst Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate
0.023
rxst Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Life
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife
P6Y1M6D
rxst Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Life
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
rxst Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend Yield
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
rxst Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend Yield
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield
0
rxst Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue
16.89
rxst Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue
12.63
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8656046
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11816582
CY2022Q4 us-gaap Share Price
SharePrice
12.67
CY2022Q2 us-gaap Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
P34M
CY2022Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2025-03-31
CY2022Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
11410
CY2023Q2 us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
5319
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2793000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3943000
CY2023Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
46000
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
206000
CY2023Q3 rxst Total Lease Assets
TotalLeaseAssets
2839000
CY2022Q4 rxst Total Lease Assets
TotalLeaseAssets
4149000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1934000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1818000
CY2023Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
42000
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
152000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1354000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2813000
CY2023Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
0
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
43000
CY2023Q3 rxst Total Lease Liabilities
TotalLeaseLiabilities
3330000
CY2022Q4 rxst Total Lease Liabilities
TotalLeaseLiabilities
4826000
CY2023Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
2000
CY2022Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
5000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
8000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
12000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
549000
CY2023Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
27000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1960000
CY2023Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
16000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1044000
CY2023Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
0
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
79000
CY2023Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
0
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0
CY2023Q3 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
0
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
0
CY2023Q3 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
0
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3632000
CY2023Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
43000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
344000
CY2023Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
1000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
3288000
CY2023Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
42000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y10M6D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y5M1D
CY2023Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y4M24D
CY2022Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M14D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.103
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.103
CY2023Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.094
CY2022Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.095
us-gaap Legal Fees
LegalFees
0
CY2022 us-gaap Legal Fees
LegalFees
0

Files In Submission

Name View Source Status
rxst-20230930_cal.xml Edgar Link unprocessable
0000950170-23-062099-index-headers.html Edgar Link pending
0000950170-23-062099-index.html Edgar Link pending
0000950170-23-062099.txt Edgar Link pending
0000950170-23-062099-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rxst-20230930.htm Edgar Link pending
rxst-20230930.xsd Edgar Link pending
rxst-ex31_1.htm Edgar Link pending
rxst-ex31_2.htm Edgar Link pending
rxst-ex32_1.htm Edgar Link pending
rxst-ex32_2.htm Edgar Link pending
Show.js Edgar Link pending
rxst-20230930_def.xml Edgar Link unprocessable
rxst-20230930_lab.xml Edgar Link unprocessable
rxst-20230930_pre.xml Edgar Link unprocessable
rxst-20230930_htm.xml Edgar Link completed